Type 2 diabetics who received injections of Novo Nordisk's Victoza had a lower level of HbA1c, a blood-sugar indicator, compared with those who were given Merck & Co.'s Januvia during a head-to-head study. The finding supports previous clinical trials that demonstrated the superiority of Victoza over rivals including Byetta, sold by Eli Lilly and Co. and Amylin Pharmaceuticals.

Full Story:

Related Summaries